Wockhardt informs about press release

16 Dec 2024 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release- ‘Zaynich™ (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.









Wockhardt Share Price

1347.55 -70.90 (-5.00%)
04-Apr-2025 15:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.55
Dr. Reddys Lab 1111.20
Cipla 1416.95
Lupin 1973.00
Zydus Lifesciences 865.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...